Article
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Rating:
0.0
Views:
52
Likes:
1
Library:
1
Sarepta's shares saw a nice boost Friday as the biotech declared its intent to seek an accelerated approval for a Roche-partnered DMD gene therapy.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value